FREE subscriptions for doctors and students... click here
You have 3 more open access pages.
Antiphospholipid syndrome (APS) is characterized by thrombosis and/or pregnancy
complications in the presence of persistent antiphospholipid antibodies (APLA)
This syndrome was first described in 1983-1986 as the association of arterial
and venous thrombosis with antibodies directed against phospholipids. (1)
The condition may occur
- in isolation as primary antiphospholipid syndrome - seen in more than
50% of patients (1)
- in association with other autoimmune diseases e.g. - SLE is the commonest
associated condition with 20-35% of patients developing secondary antiphospholipid
syndrome (1)
Laboratory diagnosis of APLA depends upon the detection of a lupus anticoagulant,
which prolongs phospholipid-dependent anticoagulation tests, and/or anticardiolipin
(aCL) and anti-beta-glycoprotein-1 (ß2GPI) antibodies
- APLA are primarily directed towards phospholipid binding proteins
- high rate of recurrent thrombosis in APS, especially in triple positive
patients (patients with lupus anticoagulants, aCL and anti-ß2GPI antibodies),
and indefinite anticoagulation with a vitamin K antagonist is the standard
of care for thrombotic APS (2)
- other clinical features, such as thrombocytopenia, Coombs-positive haemolytic
anaemia, livedo reticularis, heart valve disease, renal microangiopathy and
neurologic disorders are also common in APL-positive patients
- APS can be associated with other autoimmune disorders, such as systemic
lupus erythematosus
APS - unlike most of the genetic thrombophilias - is associated with both venous
and arterial thrombosis
- thrombosis
- deep veins of the lower extremities and the cerebral arterial circulation
are the most commonly affected venous and arterial sites, respectively
- more unusual locations can also be affected by thrombosis such as
the hepatic veins, visceral veins or cerebral venous circulation -
if there is development of thrombosis at an unusual site then this
should be prompt for antiphospholipid antibodies
- catastrophic anti-phospholipid syndrome (CAPS) develops in a small
number of patients (<1%)
- defined as small vessel thrombosis in three or more organs in less
than one week in the presence of APLA, with histopathologic confirmation
of small vessel thrombosis in the absence of inflammation
- important differential diagnosis include -thrombotic thrombocytopaenic
purpura, haemolytic uraemic syndrome, and disseminated intravascular
coagulation (2)
- CAPS is often triggered by a precipitating event such as infection
- associated with high (50%) mortality - following complications such
as cerebral and cardiac thrombosis, infections and multi-organ failure
- for patients with CAPS, a combined therapeutic approach that is complex
and includes modalities such as anticoagulation, glucocorticoids, plasma
exchange and/or intravenous immunoglobulin
Obstetrical morbidity in APS includes:
- (a) One or more unexplained deaths of a morphologically normal fetus at
or beyond the 10th week of gestation.
- (b) One or more premature births of a morphologically normal neonate before
the 34th week of gestation because of eclampsia, severe preeclampsia, or recognized
features of placental insufficiency
- (c) Three or more unexplained consecutive spontaneous abortions before
the 10th week of gestation, with maternal anatomic or hormonal abnormalities
and paternal and maternal chromosomal causes excluded.
Treatment usually comprises antithrombotic therapy using antiplatelet and anticoagulant
agents
- anticoagulant therapy with vitamin K antagonists remains the mainstay of
therapy in patients with thrombotic APS
- aspirin with low molecular weight or unfractionated heparin may reduce the
incidence of pregnancy loss in obstetric APS (2)
Reference:
Last edited 04/2019 and last reviewed 04/2019
Links: